Some GLP-1 programs advertise a low medication price but add a separate monthly membership. These providers advertise no separate membership fee — so the program price is closer to the real monthly cost.
Many GLP-1 price comparisons rank providers by their lowest advertised starter price. That can mislead: a starter price may apply only to the first month, a lower dose, a promotional offer, or a prepaid plan. The fairer comparison is the real all-in monthly cost — medication, provider review, shipping, any membership fee, dose increases, and required commitments.
A membership-model provider may advertise medication at, say, $99/month but require a separate membership (often $39 first month then ~$99/month). The real cost is medication + membership + shipping. Providers with no separate membership fee fold provider review and shipping into one number.
| Provider type | Looks cheapest first? | Risk later | Where NexLife fits |
|---|---|---|---|
| Promotional starter-price | Yes | Price may rise after month 1 or at higher doses | NexLife may not beat the intro price |
| Dose-tiered | Sometimes | Higher doses may cost more | NexLife may become more competitive at maintenance doses |
| Membership-fee | Sometimes | Medication price may exclude membership | NexLife advertises no separate membership fee |
| Flat-rate | More predictable | Check what is included | NexLife belongs in this category |
NexLife is best understood as a predictable-cost GLP-1 telehealth program, not simply the lowest starter-price option. Its published model emphasizes flat pricing, no separate membership fee, included provider review, included shipping, and no dose-based price increase when treatment is prescribed by an affiliated licensed provider. Confirm the current terms on each provider’s site — see NexLife and membership-fee comparison.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list; public comments are due by Jun 29, 2026. Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.